Neurocrine Biosciences Inc. (NBIX)$156.70
Currency: USD
Research Snapshot
Static fundamentals, valuation context, and investor signals for Neurocrine Biosciences Inc. (NBIX).
DCF ready
Valuation
20.5x
EV/FCF, 4.9% FCF yield
Quality
14.7%
ROIC, 26.2% FCF margin
Growth
22.3%
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 3.4x current ratio
Superinvestors
1
Top: Dodge & Cox (0.4%)
Strengths to research
- Revenue compounded at 22.3% over five years.
- Free cash flow compounded at 28.0% over five years.
- Free cash flow margin is healthy at 26.2%.
- Debt/equity looks manageable at 0.0x.
Watchouts
No major valuation, balance sheet, or growth watchouts were detected by the static screen.
Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for NBIX.
Grade C
55
/ 100
Financial Charts
No financial data available for NBIX (annual).
1 superinvestors own NBIX
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Dodge & Cox Dodge & Cox | 5,461,037 | $719M | 0.40% | 0.0% |